HK1185887A1 - 改良的抗體分子 - Google Patents
改良的抗體分子Info
- Publication number
- HK1185887A1 HK1185887A1 HK13113190.6A HK13113190A HK1185887A1 HK 1185887 A1 HK1185887 A1 HK 1185887A1 HK 13113190 A HK13113190 A HK 13113190A HK 1185887 A1 HK1185887 A1 HK 1185887A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibody molecules
- improved antibody
- improved
- molecules
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008248213 | 2008-09-26 | ||
JP2009060806 | 2009-03-13 | ||
JP2009067925 | 2009-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1185887A1 true HK1185887A1 (zh) | 2014-02-28 |
Family
ID=42059767
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11101085.1A HK1147107A1 (en) | 2008-09-26 | 2011-02-01 | Improved antibody molecules |
HK13113190.6A HK1185887A1 (zh) | 2008-09-26 | 2013-11-26 | 改良的抗體分子 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11101085.1A HK1147107A1 (en) | 2008-09-26 | 2011-02-01 | Improved antibody molecules |
Country Status (35)
Country | Link |
---|---|
US (8) | US8562991B2 (zh) |
EP (1) | EP2330193B1 (zh) |
JP (2) | JP4550938B2 (zh) |
KR (2) | KR101690334B1 (zh) |
CN (2) | CN103254310B (zh) |
AR (2) | AR073404A1 (zh) |
AU (1) | AU2009290162B2 (zh) |
BR (1) | BRPI0905076B8 (zh) |
CA (2) | CA2763039C (zh) |
CL (1) | CL2011000632A1 (zh) |
CO (1) | CO6362048A2 (zh) |
CR (1) | CR20110204A (zh) |
DK (1) | DK2330193T3 (zh) |
EC (1) | ECSP11011003A (zh) |
ES (1) | ES2546800T3 (zh) |
FI (1) | FIC20210049I1 (zh) |
FR (1) | FR21C1054I2 (zh) |
HK (2) | HK1147107A1 (zh) |
HR (1) | HRP20150857T1 (zh) |
HU (2) | HUE027533T2 (zh) |
IL (1) | IL211850A0 (zh) |
LT (1) | LTC2330193I2 (zh) |
MA (1) | MA32707B1 (zh) |
MX (1) | MX2010003256A (zh) |
MY (1) | MY153908A (zh) |
NL (1) | NL301152I2 (zh) |
NZ (1) | NZ592214A (zh) |
PE (1) | PE20120079A1 (zh) |
PL (1) | PL2330193T3 (zh) |
PT (1) | PT2330193E (zh) |
RU (1) | RU2430111C3 (zh) |
SI (1) | SI2330193T1 (zh) |
TW (1) | TWI440469B (zh) |
WO (1) | WO2010035769A1 (zh) |
ZA (1) | ZA201103027B (zh) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322216A1 (en) | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
AU2006305119B2 (en) | 2005-10-21 | 2012-12-20 | Chugai Seiyaku Kabushiki Kaisha | Agents for treating cardiopathy |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
CN101370521A (zh) | 2006-01-27 | 2009-02-18 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
EP4342995A2 (en) | 2006-03-31 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
CN101646459B (zh) | 2007-01-23 | 2014-02-12 | 国立大学法人信州大学 | 慢性排斥反应抑制剂 |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
MX337081B (es) | 2007-12-05 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-nr10 y su uso. |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
TWI528973B (zh) | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
RU2524152C2 (ru) * | 2009-03-19 | 2014-07-27 | Чугаи Сейяку Кабусики Кайся | Средство для лечения ревматоидного артрита |
TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
KR101436219B1 (ko) | 2009-10-26 | 2014-09-01 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
RS63800B1 (sr) | 2010-05-28 | 2022-12-30 | Chugai Pharmaceutical Co Ltd | Poboljšanje antitumorskog odgovora t ćelije |
WO2012032181A2 (en) * | 2010-09-10 | 2012-03-15 | Allozyne, Inc | Novel antibody derivatives |
BR112013011305A2 (pt) | 2010-11-08 | 2017-07-25 | Chugai Pharmaceutical Co Ltd | método de tratamento de uma disfunção mediada por il-6, método de tratamento de artrite reumatóide, artigo de fabricação, método de inibição da progressão de dano estrutural articular, composição farmacêutica, método de tratamento de artrite idiopática juvenil (jia) e método de tratamento de arterite de células gigantes (gca) |
MX355060B (es) | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea. |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US20140080153A1 (en) * | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
CN103476797A (zh) | 2011-01-28 | 2013-12-25 | 赛诺菲 | 包含针对pcsk9的人抗体的药物组合物 |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
WO2012132067A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
EP2681243B1 (en) | 2011-03-03 | 2018-09-05 | Apexigen, Inc. | Anti-il-6 receptor antibodies and methods of use |
JP5636331B2 (ja) * | 2011-04-28 | 2014-12-03 | シスメックス株式会社 | ペプチドの遊離方法および回収方法 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
ES2953713T3 (es) | 2011-09-16 | 2023-11-15 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) administrando un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
CN113416256A (zh) | 2011-11-30 | 2021-09-21 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
EP2825036B1 (en) | 2012-03-16 | 2018-05-02 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
KR102459666B1 (ko) | 2012-03-16 | 2022-10-27 | 리제너론 파마슈티칼스 인코포레이티드 | pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물 |
US9301510B2 (en) | 2012-03-16 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with pH-dependent binding characteristics |
KR101525919B1 (ko) * | 2012-05-11 | 2015-06-03 | 가톨릭대학교 산학협력단 | 자가면역 질환 예방 및 치료를 위한 tnfr2를 기반으로 하는 이중 항체 |
CA2881679C (en) * | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
TWI717591B (zh) | 2012-08-24 | 2021-02-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
BR112015008186A2 (pt) * | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
KR20210130260A (ko) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Fc영역 개변체 |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
AU2014274844B2 (en) | 2013-06-07 | 2019-11-28 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
WO2014200018A1 (ja) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法 |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
JP6616298B2 (ja) | 2013-11-12 | 2019-12-04 | サノフィ・バイオテクノロジー | Pcsk9阻害剤と共に使用するための投薬レジメン |
US10105418B2 (en) * | 2013-12-23 | 2018-10-23 | Staley A. Brod | Oral administration of tocilizumab treatment of autoimmune disease |
JP6345800B2 (ja) | 2014-03-17 | 2018-06-20 | 田辺三菱製薬株式会社 | 抗体−フィノマー複合体 |
EP3169353B1 (en) | 2014-07-16 | 2019-12-18 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
EP3240805A4 (en) | 2014-12-15 | 2018-05-09 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
CA2971186A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
MA41294A (fr) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
EP3233921B1 (en) | 2014-12-19 | 2021-09-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
CA2972393A1 (en) * | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
ES2888801T3 (es) | 2015-05-19 | 2022-01-07 | Nat Center Neurology & Psychiatry | Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM) |
WO2017031151A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
US10266590B2 (en) | 2015-09-04 | 2019-04-23 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
WO2017075433A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The University Of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
MA43377A (fr) | 2015-12-04 | 2021-05-19 | Hutchinson Fred Cancer Res | Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
AU2017238218A1 (en) | 2016-03-22 | 2018-10-11 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Early intervention methods to prevent or ameliorate toxicity |
WO2017201731A1 (en) | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
KR20190057308A (ko) | 2016-09-02 | 2019-05-28 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물 |
US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
JP7237834B2 (ja) | 2016-12-14 | 2023-03-13 | ビオラ・セラピューティクス・インコーポレイテッド | 消化管疾病のil-12/il-23阻害薬による治療 |
CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
WO2018144773A1 (en) | 2017-02-01 | 2018-08-09 | Yale University | Treatment of diuretic resistance |
EP4353818A2 (en) | 2017-02-27 | 2024-04-17 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
CN114989305A (zh) * | 2017-03-31 | 2022-09-02 | 北京智仁美博生物科技有限公司 | 新型双特异性抗体及其用途 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
EP3631468A1 (en) | 2017-06-02 | 2020-04-08 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
JP2020522489A (ja) | 2017-06-02 | 2020-07-30 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いる処置のための製造物品および方法 |
MA50057A (fr) | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
EP3698808A4 (en) | 2017-10-20 | 2021-07-14 | Hyogo College Of Medicine | MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
US20190241650A1 (en) | 2018-01-05 | 2019-08-08 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
JP7458790B2 (ja) * | 2018-01-31 | 2024-04-01 | 元一 加藤 | Il-6阻害剤を含有する喘息の治療剤 |
WO2019170845A1 (en) | 2018-03-09 | 2019-09-12 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
US11319375B2 (en) | 2018-08-29 | 2022-05-03 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
JP2022513689A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法におけるb細胞悪性腫瘍の投与および処置のための方法 |
AU2020216978A1 (en) | 2019-01-31 | 2021-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
MX2021011464A (es) * | 2019-03-29 | 2021-10-22 | Chugai Pharmaceutical Co Ltd | Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb). |
CA3135694A1 (en) | 2019-04-17 | 2020-10-22 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
SG11202112123RA (en) | 2019-05-03 | 2021-11-29 | Kite Pharma Inc | Methods of administering chimeric antigen receptor immunotherapy |
US20200405883A1 (en) | 2019-06-20 | 2020-12-31 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
CN115398231A (zh) | 2019-12-06 | 2022-11-25 | 朱诺治疗学股份有限公司 | 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法 |
WO2021150970A1 (en) | 2020-01-22 | 2021-07-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
MX2022010957A (es) | 2020-03-03 | 2023-01-24 | Twentyeight Seven Inc | Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn. |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
WO2021194865A1 (en) | 2020-03-23 | 2021-09-30 | Genentech, Inc. | Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist |
WO2021194860A1 (en) | 2020-03-23 | 2021-09-30 | Genentech, Inc. | Tocilizumab and remdesivir combination therapy for covid-19 pneumonia |
JP2023518814A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | Covid-19肺炎における、il-6アンタゴニストに対する応答を予測するためのバイオマーカー |
WO2021202919A1 (en) * | 2020-04-01 | 2021-10-07 | The University Of Chicago | Tocilizumab for the treatment of viral infections |
JP2023541921A (ja) | 2020-09-17 | 2023-10-04 | ジェネンテック, インコーポレイテッド | Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果 |
WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
US20220265719A1 (en) | 2021-02-20 | 2022-08-25 | Kite Pharma, Inc. | Immunotherapies |
EP4306127A1 (en) | 2021-03-12 | 2024-01-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment or prevention of myasthenia gravis |
AU2022274608A1 (en) | 2021-05-14 | 2023-11-09 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
WO2023119638A1 (en) * | 2021-12-24 | 2023-06-29 | Chugai Seiyaku Kabushiki Kaisha | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
WO2023095305A1 (en) * | 2021-11-26 | 2023-06-01 | Chugai Seiyaku Kabushiki Kaisha | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
WO2023095854A1 (en) * | 2021-11-26 | 2023-06-01 | Chugai Seiyaku Kabushiki Kaisha | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
US20230296610A1 (en) | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
CN114525235B (zh) * | 2022-02-25 | 2023-07-14 | 郑州大学 | 一种提高人表皮生长因子分泌生产效率的方法 |
Family Cites Families (212)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE370449B (zh) | 1970-08-29 | 1974-10-14 | Philips Nv | |
JPS5334319B2 (zh) | 1971-12-28 | 1978-09-20 | ||
JPS5717624B2 (zh) | 1974-04-17 | 1982-04-12 | ||
JPS5484060A (en) | 1977-12-12 | 1979-07-04 | Kyushu Sekisui Kogyo | Treatment of raw *wakame* by using chlorella extract |
US4324710A (en) | 1980-10-02 | 1982-04-13 | The Firestone Tire & Rubber Company | Naturally occurring thermoplastic resins as a substitute for various petroleum-derived materials in rubber stocks |
US4769320A (en) | 1982-07-27 | 1988-09-06 | New England Medical Center Hospitals, Inc. | Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations |
US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
JPH06104071B2 (ja) | 1986-08-24 | 1994-12-21 | 財団法人化学及血清療法研究所 | 第▲ix▼因子コンホメ−シヨン特異性モノクロ−ナル抗体 |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5670373A (en) * | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
IL91778A (en) | 1988-09-28 | 1994-10-07 | Lilly Co Eli | A method for reducing the heterogeneity of monoclonal antibodies |
US5126250A (en) * | 1988-09-28 | 1992-06-30 | Eli Lilly And Company | Method for the reduction of heterogeneity of monoclonal antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5202253A (en) | 1988-12-30 | 1993-04-13 | Oklahoma Medical Research Foundation | Monoclonal antibody specific for protein C and antibody purification method |
JPH0636741B2 (ja) | 1989-11-08 | 1994-05-18 | 帝人株式会社 | ヒト・プロテインcの分離方法 |
DE69130561T2 (de) | 1990-02-16 | 1999-06-24 | Boston Biomed Res Inst | Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen |
DE122009000019I1 (de) * | 1991-04-25 | 2009-07-16 | Chugai Seiyaku K K 5 1 | Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994029471A1 (en) | 1993-06-10 | 1994-12-22 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
US5945311A (en) * | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
US8017121B2 (en) * | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
RU2147443C1 (ru) | 1994-10-07 | 2000-04-20 | Чугаи Сейяку Кабусики Кайся | Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента |
EP1884524A3 (en) | 1994-10-21 | 2008-06-25 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of diseases caused by IL-6 production |
US6485943B2 (en) | 1995-01-17 | 2002-11-26 | The University Of Chicago | Method for altering antibody light chain interactions |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5830478A (en) | 1995-06-07 | 1998-11-03 | Boston Biomedical Research Institute | Method for delivering functional domains of diphtheria toxin to a cellular target |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
CZ399A3 (cs) | 1996-07-19 | 1999-06-16 | Amgen Inc. | Polypeptidová analoga kationaktivních polypeptidů |
US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP2322216A1 (en) | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
KR20080027967A (ko) | 1997-08-15 | 2008-03-28 | 츄가이 세이야꾸 가부시키가이샤 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
RU2221809C2 (ru) * | 1997-10-03 | 2004-01-20 | Тугаи Сейяку Кабусики Кайся | Способ получения природного гуманизированного антитела |
CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
HU225539B1 (en) | 1998-03-17 | 2007-02-28 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor |
AU752730B2 (en) | 1998-04-03 | 2002-09-26 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US20020142374A1 (en) * | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6475718B2 (en) | 1998-09-08 | 2002-11-05 | Schering Aktiengesellschaft | Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
WO2000032634A1 (en) * | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
CA2406650C (en) | 2000-05-03 | 2009-07-21 | Mbt Munich Biotechnology Ag | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
ES2298273T3 (es) | 2000-10-25 | 2008-05-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos o terapeuticos contra la psoriasis que contienen un antagonista de il-6 como su ingrediente activo. |
WO2002036165A1 (fr) * | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang |
JP3899804B2 (ja) | 2000-11-27 | 2007-03-28 | 富士ゼロックス株式会社 | 画像処理装置、画像処理方法および画像処理プログラムを記録した記憶媒体 |
EP2354149B1 (en) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
MXPA03008031A (es) | 2001-03-07 | 2003-12-04 | Merck Patent Gmbh | Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida. |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
UA83791C2 (ru) * | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US20040236080A1 (en) * | 2001-06-22 | 2004-11-25 | Hiroyuki Aburatani | Cell proliferation inhibitors containing anti-glypican 3 antibody |
US20040161741A1 (en) | 2001-06-30 | 2004-08-19 | Elazar Rabani | Novel compositions and processes for analyte detection, quantification and amplification |
US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
EP2308888B1 (en) * | 2001-11-14 | 2017-03-01 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
AU2003216250A1 (en) | 2002-02-11 | 2003-09-04 | Genentech, Inc. | Antibody variants with faster antigen association rates |
CN1638798A (zh) | 2002-02-14 | 2005-07-13 | 中外制药株式会社 | 包含抗体的溶液制剂 |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
WO2005056606A2 (en) | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | INTERACTION PREDICTION DEVICE |
EP1511861A4 (en) * | 2002-06-12 | 2007-12-05 | Genencor Int | METHODS AND BINDING COMPOSITIONS DEPENDENT FROM THE MEDIUM OF A TARGET AGENT TO A TARGET |
AU2003248652A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods for improving a binding characteristic of a molecule |
JP3856734B2 (ja) | 2002-06-28 | 2006-12-13 | 株式会社日立製作所 | 多発性硬化症に対するインターフェロン・ベータ薬物治療の有効性予測方法 |
AU2003264009A1 (en) | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2511598C (en) | 2002-12-24 | 2016-09-13 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
US7223393B2 (en) | 2003-02-07 | 2007-05-29 | Pdl Biopharma, Inc | Amphiregulin antibodies and their use to treat cancer and psoriasis |
PT1601697E (pt) | 2003-02-28 | 2007-09-04 | Lonza Biologics Plc | Purificação de anticorpos através de proteína a e cromatografia de troca iónica. |
JP4685764B2 (ja) | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
CA2527668A1 (en) * | 2003-06-02 | 2004-12-16 | Liquid Machines, Inc. | Managing data objects in dynamic, distributed and collaborative contexts |
BRPI0411276A (pt) | 2003-06-05 | 2006-08-01 | Genentech Inc | métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado |
WO2004113387A2 (en) | 2003-06-24 | 2004-12-29 | Merck Patent Gmbh | Tumour necrosis factor receptor molecules with reduced immunogenicity |
EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
CA2534959A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
JP2005101105A (ja) | 2003-09-22 | 2005-04-14 | Canon Inc | 位置決め装置、露光装置、デバイス製造方法 |
WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
EP2311945A1 (en) | 2003-10-14 | 2011-04-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies substituting for functional proteins |
BRPI0415505A (pt) | 2003-10-17 | 2006-12-12 | Chugai Pharmaceutical Co Ltd | agente terapêutico para mesotelioma |
PT1689777E (pt) | 2003-11-05 | 2007-05-31 | Ares Trading Sa | Processo para a purificação da proteína de ligação a il-18 |
JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法 |
DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
JP4315982B2 (ja) | 2004-01-09 | 2009-08-19 | ファイザー インコーポレイティッド | MAdCAMに対する抗体 |
BRPI0506679A (pt) | 2004-02-11 | 2007-05-15 | Warner Lambert Co | métodos de tratar osteoartrite com antagonistas de il-6 |
AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
KR20070035482A (ko) * | 2004-03-24 | 2007-03-30 | 추가이 세이야쿠 가부시키가이샤 | 인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제 |
JPWO2005090405A1 (ja) | 2004-03-24 | 2008-04-17 | 中外製薬株式会社 | インターロイキン−6受容体に対するヒト型化抗体のサブタイプ |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
WO2005112564A2 (en) | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Germline and sequence variants of humanized antibodies and methods of making and using them |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7632924B2 (en) | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
AU2005259992A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune, Llc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
WO2006023144A2 (en) | 2004-07-06 | 2006-03-02 | Bioren Inc. | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
WO2006030200A1 (en) | 2004-09-14 | 2006-03-23 | National Institute For Biological Standards And Control | Vaccine |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
NZ554520A (en) | 2004-10-22 | 2010-03-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1829961A4 (en) * | 2004-12-22 | 2008-06-04 | Chugai Pharmaceutical Co Ltd | PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED |
ES2343426T3 (es) | 2004-12-23 | 2010-07-30 | Novo Nordisk A/S | Ligandos de afinidad de union a anticuerpos. |
AU2005321974B2 (en) | 2004-12-27 | 2011-11-17 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
WO2006075668A1 (ja) | 2005-01-12 | 2006-07-20 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG2およびIgG3抗体 |
US20060275282A1 (en) * | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
WO2006109592A1 (ja) * | 2005-04-08 | 2006-10-19 | Chugai Seiyaku Kabushiki Kaisha | 血液凝固第viii因子の機能代替抗体 |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
DK2573114T3 (en) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | The identification and production of antibodies with variant Fc regions, and methods of using same |
CN103450359B (zh) | 2005-08-19 | 2018-07-24 | 惠氏有限责任公司 | 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途 |
WO2007041317A2 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
AU2006305119B2 (en) | 2005-10-21 | 2012-12-20 | Chugai Seiyaku Kabushiki Kaisha | Agents for treating cardiopathy |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
WO2007061029A1 (ja) | 2005-11-25 | 2007-05-31 | Keio University | 前立腺癌治療剤 |
EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
DK3219328T3 (da) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
CN101370521A (zh) | 2006-01-27 | 2009-02-18 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
WO2007092772A2 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
US8048421B2 (en) * | 2006-03-23 | 2011-11-01 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
EP4342995A2 (en) | 2006-03-31 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
BRPI0711908B8 (pt) * | 2006-05-25 | 2021-05-25 | Glaxo Group Ltd | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
DK2047863T3 (da) | 2006-06-08 | 2013-09-16 | Chugai Pharmaceutical Co Ltd | Middel til forebyggelse eller behandling af inflammatoriske sygdomme |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
CA3163418A1 (en) | 2006-10-06 | 2008-05-22 | Jeffrey S. Isenberg | Prevention of tissue ischemia, related methods and compositions |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
CN101646459B (zh) | 2007-01-23 | 2014-02-12 | 国立大学法人信州大学 | 慢性排斥反应抑制剂 |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
WO2008145141A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
ES2557328T3 (es) * | 2007-06-18 | 2016-01-25 | Inventio Ag | Dispositivo y procedimiento para controlar un dispositivo de frenado |
EP3543691A1 (en) | 2007-06-29 | 2019-09-25 | Quest Diagnostics Investments Incorporated | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
WO2009010539A2 (en) | 2007-07-19 | 2009-01-22 | Ablynx. N.V. | Receptor for interleukin-6 (il-6) from macaca fascicularis |
EP2174667B1 (en) | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
US20100226925A1 (en) | 2007-09-14 | 2010-09-09 | Amgen Inc. | Homogeneous Antibody Populations |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
WO2009041734A1 (ja) | 2007-09-26 | 2009-04-02 | Kyowa Hakko Kirin Co., Ltd. | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
AR068564A1 (es) | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti- receptor de il-6 (interleuquina 6) |
MX2010003450A (es) * | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
AU2008305851B2 (en) | 2007-09-28 | 2014-12-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
KR101601986B1 (ko) | 2007-10-02 | 2016-03-17 | 추가이 세이야쿠 가부시키가이샤 | 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
MX337081B (es) | 2007-12-05 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-nr10 y su uso. |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
KR101666229B1 (ko) | 2008-02-08 | 2016-10-14 | 메디뮨 엘엘씨 | Fc 리간드 친화성이 감소된 항-IFNAR1 항체 |
KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
ES2487846T3 (es) | 2008-05-01 | 2014-08-25 | Amgen, Inc. | Anticuerpos anti-hepcindina y métodos de uso |
TWI528973B (zh) | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP5913980B2 (ja) | 2008-10-14 | 2016-05-11 | ジェネンテック, インコーポレイテッド | 免疫グロブリン変異体及びその用途 |
NZ602166A (en) | 2008-11-25 | 2014-02-28 | Alder Biopharmaceuticals Inc | Antibodies to il-6 and use thereof |
EP2400981A4 (en) | 2009-02-26 | 2013-02-27 | Lpath Inc | DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES |
WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP4885308B2 (ja) | 2009-03-19 | 2012-02-29 | 中外製薬株式会社 | 改良された抗体分子を含有する製剤 |
TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
RU2524152C2 (ru) | 2009-03-19 | 2014-07-27 | Чугаи Сейяку Кабусики Кайся | Средство для лечения ревматоидного артрита |
WO2011013786A1 (ja) | 2009-07-31 | 2011-02-03 | Maeda Shin | 癌の転移抑制剤 |
US10150808B2 (en) * | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US9624290B2 (en) | 2010-01-28 | 2017-04-18 | Ab Biosciences, Inc. | Lowered affinity antibodies and methods of making the same |
AU2011217770B2 (en) | 2010-02-19 | 2016-02-04 | Xencor, Inc. | Novel CTLA4-IG immunoadhesins |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
KR20120138241A (ko) | 2010-03-11 | 2012-12-24 | 화이자 인코포레이티드 | pH 의존성 항원 결합을 갖는 항체 |
TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
WO2011149046A1 (ja) | 2010-05-28 | 2011-12-01 | 独立行政法人国立がん研究センター | 膵癌治療剤 |
RS63800B1 (sr) | 2010-05-28 | 2022-12-30 | Chugai Pharmaceutical Co Ltd | Poboljšanje antitumorskog odgovora t ćelije |
BR112013011305A2 (pt) | 2010-11-08 | 2017-07-25 | Chugai Pharmaceutical Co Ltd | método de tratamento de uma disfunção mediada por il-6, método de tratamento de artrite reumatóide, artigo de fabricação, método de inibição da progressão de dano estrutural articular, composição farmacêutica, método de tratamento de artrite idiopática juvenil (jia) e método de tratamento de arterite de células gigantes (gca) |
JPWO2012063875A1 (ja) | 2010-11-11 | 2014-05-12 | シスメックス株式会社 | ヒト濾胞ヘルパーt細胞検出用マーカーおよびヒト濾胞ヘルパーt細胞の検出方法 |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
BR112013021725A2 (pt) | 2011-02-28 | 2016-11-01 | Genentech Inc | marcadores biológicos e métodos para prever resposta aos antagonistas de células b |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
US20150299313A1 (en) | 2011-10-05 | 2015-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain |
CN113416256A (zh) | 2011-11-30 | 2021-09-21 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
TW202015731A (zh) | 2012-02-24 | 2020-05-01 | 日商中外製藥股份有限公司 | 經FcγRIIB促進抗原消失之抗原結合分子 |
US20150353630A1 (en) | 2012-05-30 | 2015-12-10 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
CA2881679C (en) | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
WO2014144080A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
US9321686B2 (en) | 2013-03-15 | 2016-04-26 | Forta Corporation | Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete |
KR20210130260A (ko) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Fc영역 개변체 |
WO2014200018A1 (ja) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法 |
NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
ES2888801T3 (es) | 2015-05-19 | 2022-01-07 | Nat Center Neurology & Psychiatry | Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM) |
-
2009
- 2009-09-16 TW TW098131191A patent/TWI440469B/zh active
- 2009-09-25 RU RU2010111890A patent/RU2430111C3/ru active Protection Beyond IP Right Term
- 2009-09-25 CA CA2763039A patent/CA2763039C/en not_active Expired - Fee Related
- 2009-09-25 AU AU2009290162A patent/AU2009290162B2/en active Active
- 2009-09-25 PT PT98161847T patent/PT2330193E/pt unknown
- 2009-09-25 DK DK09816184.7T patent/DK2330193T3/en active
- 2009-09-25 US US12/680,087 patent/US8562991B2/en active Active
- 2009-09-25 CN CN201310127358.6A patent/CN103254310B/zh not_active Expired - Fee Related
- 2009-09-25 WO PCT/JP2009/066590 patent/WO2010035769A1/ja active Application Filing
- 2009-09-25 MX MX2010003256A patent/MX2010003256A/es active IP Right Grant
- 2009-09-25 PE PE2011000788A patent/PE20120079A1/es not_active Application Discontinuation
- 2009-09-25 MY MYPI2010001102A patent/MY153908A/en unknown
- 2009-09-25 KR KR1020107007644A patent/KR101690334B1/ko active IP Right Grant
- 2009-09-25 PL PL09816184T patent/PL2330193T3/pl unknown
- 2009-09-25 JP JP2009552949A patent/JP4550938B2/ja active Active
- 2009-09-25 BR BRPI0905076A patent/BRPI0905076B8/pt active IP Right Grant
- 2009-09-25 CA CA2699834A patent/CA2699834C/en active Active
- 2009-09-25 CN CN2009801007096A patent/CN101849006B/zh active Active
- 2009-09-25 KR KR1020107007620A patent/KR101044180B1/ko active IP Right Grant
- 2009-09-25 SI SI200931268T patent/SI2330193T1/sl unknown
- 2009-09-25 ES ES09816184.7T patent/ES2546800T3/es active Active
- 2009-09-25 HU HUE09816184A patent/HUE027533T2/en unknown
- 2009-09-25 EP EP09816184.7A patent/EP2330193B1/en active Active
- 2009-09-25 NZ NZ592214A patent/NZ592214A/xx not_active IP Right Cessation
- 2009-09-25 AR ARP090103711A patent/AR073404A1/es active IP Right Grant
-
2010
- 2010-01-26 JP JP2010013833A patent/JP5661291B2/ja active Active
-
2011
- 2011-02-01 HK HK11101085.1A patent/HK1147107A1/xx unknown
- 2011-03-22 IL IL211850A patent/IL211850A0/en unknown
- 2011-03-24 CL CL2011000632A patent/CL2011000632A1/es unknown
- 2011-04-12 CO CO11045364A patent/CO6362048A2/es active IP Right Grant
- 2011-04-12 MA MA33765A patent/MA32707B1/fr unknown
- 2011-04-15 CR CR20110204A patent/CR20110204A/es unknown
- 2011-04-19 ZA ZA2011/03027A patent/ZA201103027B/en unknown
- 2011-04-25 EC EC2011011003A patent/ECSP11011003A/es unknown
-
2012
- 2012-06-15 US US13/524,528 patent/US20120253016A1/en not_active Abandoned
-
2013
- 2013-11-26 HK HK13113190.6A patent/HK1185887A1/zh not_active IP Right Cessation
-
2014
- 2014-10-22 US US14/520,423 patent/US10662245B2/en active Active
-
2015
- 2015-08-11 HR HRP20150857TT patent/HRP20150857T1/hr unknown
-
2020
- 2020-04-02 US US16/838,415 patent/US20200231688A1/en not_active Abandoned
-
2021
- 2021-10-25 US US17/509,128 patent/US20220041741A1/en not_active Abandoned
- 2021-11-10 FR FR21C1054C patent/FR21C1054I2/fr active Active
- 2021-11-12 HU HUS2100050C patent/HUS2100050I1/hu unknown
- 2021-11-17 LT LTPA2021013C patent/LTC2330193I2/lt unknown
- 2021-12-08 NL NL301152C patent/NL301152I2/nl unknown
- 2021-12-13 FI FIC20210049C patent/FIC20210049I1/fi unknown
-
2022
- 2022-06-01 US US17/829,641 patent/US20220306755A1/en not_active Abandoned
- 2022-09-08 AR ARP220102433A patent/AR127010A2/es unknown
-
2023
- 2023-01-12 US US18/096,066 patent/US20230159648A1/en not_active Abandoned
- 2023-09-11 US US18/464,407 patent/US20240010738A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1185887A1 (zh) | 改良的抗體分子 | |
GB0903325D0 (en) | Antibody molecules | |
ZA201102119B (en) | Improved antibody libraies | |
EP3064512C0 (en) | ANTIBODIES AGAINST CLDN6 | |
GB0815109D0 (en) | Polydialkylsiloxane-bridged bi-photochromic molecules | |
EP2285384A4 (en) | BORN SMALL MOLECULES | |
GB0821100D0 (en) | Antibodies | |
EP2351777A4 (en) | ANTI-MUC1 ANTIBODIES | |
EP2348863A4 (en) | BORN SMALL MOLECULES | |
HK1136970A1 (zh) | 五特異性抗體 | |
PT2374883T (pt) | Anticorpo anti-cd4 | |
EP2138576A4 (en) | ANTI-CLAUDIN-4 ANTIBODY | |
EP2337798A4 (en) | BSA-SPECIFIC ANTIBODIES | |
ZA201007955B (en) | Anti-cxcr4 antibodies | |
IL218544A0 (en) | Dll4-binding molecules | |
EP2259795A4 (en) | ANTI-VEGF ANTIBODY | |
EP2172483A4 (en) | ANTI-MUC17 ANTIBODY | |
ZA201006099B (en) | Anti-tyrp1 antibodies | |
IL205073A0 (en) | Anti-bst2 antibody | |
EP2274332A4 (en) | ANTI-TNF ALPHA ANTIBODY | |
ZA201007976B (en) | Anti-pirb antibodies | |
EP2318436A4 (en) | ANTIBODIES OF DIFFERENT DOMAINS | |
GB0818356D0 (en) | Antibodies | |
EP2336311A4 (en) | ANTI-VASA ANTIBODY OF TUNA | |
GB0911770D0 (en) | Antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190923 |